The results for Rem-L alone did not look compelling (barely under p < 0.05 with a population subset selection post-hoc) but the results for Rem-L with dexamethasone looks quite good and should be of good interest to Novartis. Not sure it will be enough for approval though without further trials.
Once again, had Mesoblast excluded older people from the ARDS trial cohort (lots of people on here were worried about this before results were released) then the trial would likely have met its end point and got approved. Comes down to management of these trials and reactivity through the safety board to inclusion criteria etc.
This is at least some good news for holders.
- Forums
- ASX - By Stock
- MSB
- Ann: COVID ARDS Trial Topline 60-Day Results
Ann: COVID ARDS Trial Topline 60-Day Results, page-13
-
- There are more pages in this discussion • 1,616 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
95.0¢ |
Change
-0.015(1.55%) |
Mkt cap ! $1.084B |
Open | High | Low | Value | Volume |
96.5¢ | 96.5¢ | 94.5¢ | $2.433M | 2.552M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 72431 | 94.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
95.0¢ | 20225 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 3206 | 0.950 |
4 | 33416 | 0.945 |
4 | 35535 | 0.940 |
4 | 37778 | 0.935 |
5 | 43150 | 0.930 |
Price($) | Vol. | No. |
---|---|---|
0.905 | 13161 | 1 |
0.950 | 4147 | 1 |
0.955 | 15173 | 1 |
0.960 | 26500 | 1 |
0.965 | 42426 | 3 |
Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
SPONSORED BY The Market Online